CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022

Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ruihao, Wen, Qin, Zhang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082521/
https://www.ncbi.nlm.nih.gov/pubmed/37029381
http://dx.doi.org/10.1186/s13045-023-01435-3
_version_ 1785021330138071040
author Huang, Ruihao
Wen, Qin
Zhang, Xi
author_facet Huang, Ruihao
Wen, Qin
Zhang, Xi
author_sort Huang, Ruihao
collection PubMed
description Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in NK cell engineering, target design and combination with other agents to treat relapsed or refractory hematological malignancies, especially acute myeloid leukemia and multiple myeloma. This correspondence summarizes the preclinical and clinical updates for universal CAR-NK cell therapy reported at the ASH 2022 annual meeting.
format Online
Article
Text
id pubmed-10082521
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100825212023-04-09 CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022 Huang, Ruihao Wen, Qin Zhang, Xi J Hematol Oncol Correspondence Chimeric antigen receptor (CAR)-NK cell therapy has the advantages of a low incidence of side effects and a low cost. However, the clinical outcomes are not satisfactory due to limited antitumor effects and a limited proliferative capacity. Recently, progress in CAR-NK cell therapy has been made in NK cell engineering, target design and combination with other agents to treat relapsed or refractory hematological malignancies, especially acute myeloid leukemia and multiple myeloma. This correspondence summarizes the preclinical and clinical updates for universal CAR-NK cell therapy reported at the ASH 2022 annual meeting. BioMed Central 2023-04-07 /pmc/articles/PMC10082521/ /pubmed/37029381 http://dx.doi.org/10.1186/s13045-023-01435-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Huang, Ruihao
Wen, Qin
Zhang, Xi
CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
title CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
title_full CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
title_fullStr CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
title_full_unstemmed CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
title_short CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
title_sort car-nk cell therapy for hematological malignancies: recent updates from ash 2022
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082521/
https://www.ncbi.nlm.nih.gov/pubmed/37029381
http://dx.doi.org/10.1186/s13045-023-01435-3
work_keys_str_mv AT huangruihao carnkcelltherapyforhematologicalmalignanciesrecentupdatesfromash2022
AT wenqin carnkcelltherapyforhematologicalmalignanciesrecentupdatesfromash2022
AT zhangxi carnkcelltherapyforhematologicalmalignanciesrecentupdatesfromash2022

Ejemplares similares